Human tissue in systems medicine
暂无分享,去创建一个
Peter D Caie | David J Harrison | Klaas Schuur | Anca Oniscu | P. Caie | A. Oniscu | D. Harrison | P. Mullen | P. Reynolds | Peter Mullen | Paul A Reynolds | K. Schuur
[1] Leslie H. Sobin,et al. TNM Classification of Malignant Tumours, 7th Edition , 2009 .
[2] O. Laerum,et al. Clinical application of flow cytometry: a review. , 1981, Cytometry.
[3] Neil O Carragher,et al. High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells , 2010, Molecular Cancer Therapeutics.
[4] G. Fontanini,et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer , 2009, British Journal of Cancer.
[5] M. Nowak,et al. Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.
[6] Josep Tabernero,et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] W. McGuire,et al. Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques. , 1992, Anticancer research.
[8] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Lewis C Cantley,et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy , 2013, Nature Medicine.
[10] F.A.M. Bordonaba,et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .
[11] Francesca Molinari,et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.
[12] L. Hood,et al. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. , 2012, New biotechnology.
[13] V. Speirs,et al. Breast cancer: Investment biobanking—increased returns from tissue samples , 2013, Nature Reviews Clinical Oncology.
[14] Andrew Evans,et al. Digital imaging in pathology: whole-slide imaging and beyond. , 2013, Annual review of pathology.
[15] G. Giaccone,et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, The Journal of molecular diagnostics : JMD.
[16] Richard L Schilsky,et al. Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.
[17] David J. Harrison,et al. Systems pathology—taking molecular pathology into a new dimension , 2009, Nature Reviews Clinical Oncology.
[18] Robert C. Wolpert,et al. A Review of the , 1985 .
[19] H. Ling. KRAS Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer , 2009 .
[20] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] B. Freedman,et al. A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues. , 1975, Clinica chimica acta; international journal of clinical chemistry.
[22] F. Markowetz,et al. Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling , 2012, Science Translational Medicine.
[23] L. Sobin,et al. TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.
[24] J. Brierley. Classification of Malignant Tumours , 1963, British medical journal.
[25] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[26] Igor Goryanin,et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. , 2009, Cancer research.
[27] C. von Wagner,et al. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests , 2010, Gut.
[28] D Faratian,et al. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[30] M. Dowsett,et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer , 2010, Breast Cancer Research.
[31] Robert Brian Jenkins,et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[32] D. Calvisi,et al. Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: novel insights from interspecies comparison. , 2012, Biochimica et biophysica acta.
[33] Leslie H. Sobin,et al. Comprar TNM Classification of Malignant Tumours, 7th Edition | C. Wittekind | 9781444332414 | Wiley , 2009 .
[34] Marilyn M. Bui,et al. Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it? , 2010, Journal of pathology informatics.
[35] Girish Venkataraman,et al. Validation of World Health Organization/International Society of Urologic Pathology 2004 classification schema for bladder urothelial carcinomas using quantitative nuclear morphometry: identification of predictive features using bootstrap method. , 2007, Urology.